Number of Phase I Clinical Trial Singapore, Clinical Trials Market Singapore - Ken Research
by Ashish Kumar Market ResearcherThe report titled “Singapore Contract Research Organization Market Outlook to 2022 - by
Phase I, Phase II, Phase III, Phase IV, Pre-Clinical Market, Data Management,
Biostatistics, Central Laboratory Services, Pharmacovigilance, Bioanalytics and
HEOR” covers
aspects such as CRO market segment (by Phase I, Phase II, Phase III, Phase IV,
Pre-Clinical Market, Data Management, Biostatistics, Central Laboratory
Services, Pharmacovigilance, Bioanalytics and HEOR), by Number of Clinical
Trials, by Therapeutic Area (Oncology, Clinical Pharmacology, gastroenterology
& hepatology, Dermatology, cardiology, diagnostic imaging, infectious
diseases, ophthalmology and others), and covering competitive landscape of
major CRO companies including Singapore Clinical Research Institute (SCRI), Phoenix
Pharma Central Services (S) Pte Ltd, Maccine Pte Ltd, Covance (Asia) Pte Ltd,
Quintiles East Asia Pte Ltd, EPS Global Research Pte Ltd., ICON Clinical
Research Pte Ltd, PPD Development (S) Pte Ltd, PAREXEL International
Corporation, PRA Singapore, Syneos Health, Novotech, and SGS. The report
concludes with market projection for future and analyst recommendations
highlighting the major opportunities and cautions.
Singapore CRO Market
Singapore CRO market has inclined at positive CAGR during
2013-2017. The market is majorly driven by patent expiration of main
revenue-generating drugs, competition from the generic versions of branded
drugs, and increasing research and development costs which have pushed
pharmaceuticals manufacturers to look for strategies to cut costs and speed up
the R&D processes. The manufacturers struggle to renew their pipelines
while facing the challenges of efficient drug discovery which has propelled
growth in the contract research outsourcing industry in Singapore. Further, the
market is supported by best in class infrastructure for research, highly
skilled workforce, Strong intellectual property (IP) and legal infrastructure
and government support.
Singapore CRO Market
Segmentation
The CRO market includes revenue generated from Phase I, II,
II, IV clinical trials, Pre-clinical market, data management, biostatistics,
and central laboratory services, Pharmacovigilance, Bioanalytics and HEOR.
Growing emphasis on translational research within pharmaceutical R&D due to
the government’s commitment to scientific research has propelled the growth of
pre-clinical market in Singapore. Early phase clinical trials such as Phase I
and Phase II are rising rapidly owing to its small patient pool, strong legal
and political system, world-class infrastructure and connectivity, and access
to talents. Other services such as Pharmacovigilance has witnessed increase in
revenue as their scope expanded from just addressing ADR (Adverse Drug
Reaction) to risk management plans and also because it also complies with local
and global regulations. Bioanalytics is growing, as high cost and risk has led
pharmaceutical companies to outsource more of pre-clinical and early phase
development services.
The oncology segment has accounted for more than half of the
clinical trials in 2015. Major factor driving the oncology segment include
rising cases of cancer, availability of government funding for research
purposes, and growing expertise for cancer by CROs. Other major therapeutic
segments include clinical pharmacology, gastroenterology & hepatology,
cardiology, diagnostic imaging, infectious diseases, ophthalmology and others.
Singapore CRO Market
Competition Overview
CRO market in Singapore is dominated by MNCs that are
capitalizing on the increasing government support for clinical research and
foreign investment. The number of clinical trials increased due to
establishment of more clinical trial units and more patient participation that
gives them the opportunity to access innovative experimental treatments that are
not yet available in the market. The market is concentrated with top 10
companies occupying more than half of the overall market revenue. Major
competition parameters include service portfolio and therapeutic areas covered
by the Contract Research organization
Singapore CRO Market
Future Potential
Singapore CRO market is expected to grow at a positive CAGR
during 2018-2022. The two most significant market growth drivers are the
reduction of drug lag and cost. Other growth drivers such as vendor consolidation
and increased outsourcing penetration will further augment the CRO market in
Singapore.
Key Topics Covered in
the Report:
Singapore CRO Market Size, 2013-2017
Singapore Phase I, Phase II, Phase II, Phase IV, Data
Management, Pre-Clinical, Biostatistics, Central Laboratory Services,
Pharmacovigilance, Bioanalytics, and HEOR Market Size, 2013-2017
Singapore CRO Market Segmentation (by Major Therapeutic
Segments and by Phase of Clinical Trial)
Trends and Developments in Singapore CRO Market
Government Initiatives, Rules and Regulations in Singapore
CRO Market
Singapore CRO Market Competitive Landscape
Singapore CRO Future Outlook and Projections, 2018-2022
Value Chain in Singapore CRO Industry
Products Covered:
CRO market segment (by Phase I, Phase II, Phase III, Phase
IV, Pre-Clinical Market, Data Management, Biostatistics, Central Laboratory
Services, Pharmacovigilance, Bioanalytics and HEOR),by Number of Clinical
Trials by Therapeutic Area (Oncology, Clinical Pharmacology, gastroenterology
& hepatology, Dermatology, cardiology, diagnostic imaging, infectious
diseases, ophthalmology and others)
Companies Covered:
Singapore Clinical Research Institute (SCRI), Phoenix Pharma
Central Services (S) Pte Ltd, Maccine Pte Ltd, Covance (Asia) Pte Ltd,
Quintiles East Asia Pte Ltd, EPS Global Research Pte Ltd., ICON Clinical
Research Pte Ltd, PPD Development (S) Pte Ltd, PAREXEL International
Corporation, PRA Singapore, Syneos Health, Novotech, and SGS
For more information on
the research report, refer to below link:
Related Reports by Ken
Research
https://www.kenresearch.com/healthcare/general-healthcare/uae-healthcare-market-report/37505-91.html
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
+91-9015378249
Sponsor Ads
Created on Jul 10th 2018 02:13. Viewed 682 times.